Literature DB >> 34111961

A picture is worth a thousand words: a history of diagnostic imaging for lymphoma.

N Ari Wijetunga1, Brandon Stuart Imber1, James F Caravelli2, N George Mikhaeel3, Joachim Yahalom1.   

Abstract

The journey from early drawings of Thomas Hodgkin's patients to deep learning with radiomics in lymphoma has taken nearly 200 years, and in many ways, it parallels the journey of medicine. By tracing the history of imaging in clinical lymphoma practice, we can better understand the motivations for current imaging practices. The earliest imaging modalities of the 2D era each had varied, site-dependent sensitivity, and the improved accuracy of imaging studies allowed new diagnostic and therapeutic techniques. First, we review the initial imaging technologies that were applied to understand lymphoma spread and achieve practical guidance for the earliest lymphoma treatments. Next, in the 3D era, we describe how anatomical imaging advances replaced and complemented conventional modalities. Afterward, we discuss how the PET era scans were used to understand response of tumors to treatment and risk stratification. Finally, we discuss the emergence of radiomics as a promising area of research in personalized medicine. We are now able to identify involved lymph nodes and body sites both before and after treatment to offer patients improved treatment outcomes. As imaging methods continue to improve sensitivity, we will be able to use personalized medicine approaches to give targeted and highly focused therapies at even earlier time points, and ideally, we can obtain long-term disease control and cures for lymphomas.

Entities:  

Mesh:

Year:  2021        PMID: 34111961      PMCID: PMC8553205          DOI: 10.1259/bjr.20210285

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  126 in total

1.  Detection of lymphoma in bone marrow by whole-body positron emission tomography.

Authors:  R Carr; S F Barrington; B Madan; M J O'Doherty; C A Saunders; J van der Walt; A R Timothy
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

2.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

Authors:  T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

3.  18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.

Authors:  F Moog; M Bangerter; J Kotzerke; A Guhlmann; N Frickhofen; S N Reske
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

4.  Residual mass in lymphoma may not be residual disease.

Authors:  G P Canellos
Journal:  J Clin Oncol       Date:  1988-06       Impact factor: 44.544

5.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

Authors:  Heiko Schöder; Ariela Noy; Mithat Gönen; Lijun Weng; David Green; Yusuf E Erdi; Steven M Larson; Henry W D Yeung
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

6.  Whole body positron emission tomography in the treatment of Hodgkin disease.

Authors:  B Hueltenschmidt; M L Sautter-Bihl; O Lang; F D Maul; J Fischer; H G Mergenthaler; H Bihl
Journal:  Cancer       Date:  2001-01-15       Impact factor: 6.860

7.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Authors:  Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

8.  Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.

Authors:  Robert H Blum; John F Seymour; Andrew Wirth; Michael MacManus; Rodney J Hicks
Journal:  Clin Lymphoma       Date:  2003-06

9.  FDG-PET for predicting the prognosis of malignant lymphoma.

Authors:  J Okada; H Oonishi; K Yoshikawa; J Itami; K Uno; K Imaseki; N Arimizu
Journal:  Ann Nucl Med       Date:  1994-08       Impact factor: 2.668

10.  Predicting malignancy grade with PET in non-Hodgkin's lymphoma.

Authors:  M Rodriguez; S Rehn; H Ahlström; C Sundström; B Glimelius
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

View more
  1 in total

1.  Lymphoma: advances in imaging and radiotherapy - introductory editorial.

Authors:  Tim Illidge; N George Mikhaeel; Lena Specht; Joachim Yahalom
Journal:  Br J Radiol       Date:  2021-11-01       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.